RecruitingPHASE1, PHASE2NCT07450391
EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
Studying Epstein-Barr virus-associated malignant lymphoproliferative disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Daihong Liu
- Principal Investigator
- Daihong LiuChinese PLA General Hospital
- Intervention
- EBV-AST Cell Injection(biological)
- Enrollment
- 18 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Chinese PLA General Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07450391 on ClinicalTrials.govOther trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder
Additional recruiting or active studies for the same condition.
See all trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder →